This Is MS Multiple Sclerosis Knowledge & Support Community

Scientists in Australia begin preclinical study that may help halt MS progression Researchers from Monash University in Australia are set to conduct a large study into a drug that may one day help halt the progression of multiple sclerosis (MS)...Read more - http://www.ms-uk.org/scientists-australia...

Scientists reveal the workings of key molecular mechanism of autoimmune and inflammatory diseases An international team of researchers led by Professor Savvas Savvides, VIB-UGent Center for Inflammation Research, has unravelled a crucial aspect of the molecular basis of autoimmune and inflammatory d...

FDA denies health claim for healthy people to take vitamin D to reduce the risk of MS The U.S Food and Drug Administration (FDA) has denied a request for healthy individuals to consume vitamin D to reduce the risk of developing multiple sclerosis (MS)...Read more - http://www.ms-uk.org/fda-denies-he...

Ocrelizumab is granted EU licence for primary progressive and relapsing remitting MS The European Commission (EC) has granted a licence for the use of ocrelizumab, also known as Ocrevus, in people with primary progressive multiple sclerosis (PPMS) and relapsing remitting multiple sclerosis (RRMS)…Re...

Back in July 2017, the Medical and Healthcare products Regulatory Agency (MHRA) highlighted restrictions on the use of daclizumab (Zinbryta) for relapsing remitting multiple sclerosis (RRMS) during an urgent EU review into the risk of severe liver injury... Read more - http://www.ms-uk.org/new-restr...

Rituximab ‘superior to all other DMT in terms of drug discontinuation’ study finds Scientists have conducted a study that looks at how traditional initial disease modifying treatment (DMT) choices, including dimethyl fumarate, fingolimod, or natalizumab compare with rituximab in relapsing remitting ...

Multiple sclerosis: Cholesterol crystals prevent regeneration in central nervous system The regeneration of intact myelin sheaths is a necessary prerequisite for patients to recover from multiple sclerosis (MS) relapses. Nevertheless, the body's ability to regenerate myelin decreases with age...Read...

Revised 'McDonald Criteria' expected to speed up the diagnosis of multiple sclerosis The McDonald Criteria, used for the diagnosis of multiple sclerosis (MS), has been revised by a 30-member international panel of MS experts co-chaired by Jeffrey Cohen, MD (Cleveland Clinic) and Alan Thompson, MD (U...

NICE proposes the withdrawal of six disease modifying drugs used to treat relapsing remitting and secondary progressive MS The Department of Health has asked the National Institute for Health and Care Excellence (NICE) to produce guidance on using beta interferons and glatiramer acetate for the trea...

Medday withdraws licencing application for high dose Biotin for progressive MSers Medday, the makers of Biotin have formally withdrawn their application for EMA (European Medicines Agency) marketing authorisation for progressive MS drug Qizenday... Read more - http://www.ms-uk.org/medday-withdraws-l...

Fingolimod granted FDA Breakthrough Therapy designation for paediatric MS Novartis today announced that the US Food and Drug Administration (FDA) has granted Breakthrough Therapy designation for fingolimod for the treatment of children and adolescents 10 years of age or older with relapsing multiple...

Diet quality is associated with disability and symptom severity in MS A study of around 7,000 people with MS in North America has assessed how diet quality is associated with disability...Read more - http://www.ms-uk.org/diet-quality-associated-disability-and-symptom-severity-ms https://scontent-lht...

Insights into how the body clock and time of day influence immune responses have been revealed in a study published in the journal Nature Communications...Read more - http://www.ms-uk.org/time-day-affects-severity-autoimmune-disease https://scontent-lht6-1.xx.fbcdn.net/v/t1.0-9/22090095_158530277150...

More effective multiple sclerosis medicines and improved services offer new hopes for disability prevention New international research finds that people living with multiple sclerosis (MS) prioritise slowing disease progression when considering treatment choices. People with MS want therapies that r...

Researchers to study a new way to deliver MS drugs to the brain Two researchers in the department of anatomy and cell biology in the University of Illinois at Chicago (UIC) College of Medicine have received a seed grant to develop a new drug delivery method that holds promise in the treatment of mul...